Amgen (AMGN) Scheduled to Post Quarterly Earnings on Wednesday

Amgen (NASDAQ:AMGNGet Rating) is set to post its quarterly earnings results after the market closes on Wednesday, April 27th. Analysts expect Amgen to post earnings of $4.20 per share for the quarter.

Amgen (NASDAQ:AMGNGet Rating) last announced its earnings results on Monday, February 7th. The medical research company reported $4.36 EPS for the quarter, topping the consensus estimate of $4.14 by $0.22. The business had revenue of $6.85 billion during the quarter, compared to the consensus estimate of $6.87 billion. Amgen had a net margin of 22.68% and a return on equity of 120.59%. Amgen’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.81 EPS. On average, analysts expect Amgen to post $18 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Amgen stock traded up $1.00 during trading hours on Thursday, hitting $256.38. The company had a trading volume of 4,218 shares, compared to its average volume of 3,110,438. The firm has a 50-day moving average of $236.17 and a 200 day moving average of $223.39. The company has a debt-to-equity ratio of 4.96, a current ratio of 1.59 and a quick ratio of 1.26. The firm has a market cap of $136.85 billion, a PE ratio of 24.85, a PEG ratio of 1.52 and a beta of 0.59. Amgen has a one year low of $198.64 and a one year high of $261.00.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 8th. Stockholders of record on Tuesday, May 17th will be paid a dividend of $1.94 per share. The ex-dividend date of this dividend is Monday, May 16th. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.03%. Amgen’s dividend payout ratio (DPR) is currently 75.27%.

Institutional investors have recently made changes to their positions in the stock. Barclays PLC increased its position in Amgen by 48.0% during the 4th quarter. Barclays PLC now owns 3,033,778 shares of the medical research company’s stock worth $682,507,000 after purchasing an additional 984,406 shares in the last quarter. Morgan Stanley grew its stake in shares of Amgen by 0.8% during the second quarter. Morgan Stanley now owns 10,040,932 shares of the medical research company’s stock worth $2,447,476,000 after buying an additional 80,922 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of Amgen by 126.2% during the fourth quarter. NewEdge Advisors LLC now owns 28,435 shares of the medical research company’s stock worth $6,397,000 after buying an additional 15,865 shares in the last quarter. EverSource Wealth Advisors LLC bought a new position in shares of Amgen in the 4th quarter valued at $557,000. Finally, Titleist Asset Management LTD. acquired a new stake in shares of Amgen during the 4th quarter valued at $346,000. 74.53% of the stock is currently owned by institutional investors.

AMGN has been the topic of a number of research reports. Bank of America lowered Amgen from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $285.00 to $255.00 in a report on Wednesday, January 5th. Morgan Stanley lowered their price target on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 12th. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 5th. Barclays increased their target price on shares of Amgen from $233.00 to $236.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 12th. Finally, Wells Fargo & Company lifted their price target on shares of Amgen from $210.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 9th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus price target of $235.24.

About Amgen (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Further Reading

Earnings History for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.